🇺🇸 FDA
Patent

US 7071205

5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds

granted A61PA61P15/00A61P15/08

Quick answer

US patent 7071205 (5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds) held by Ligand Pharmaceuticals Incorporated expires Mon Jun 29 2026 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ligand Pharmaceuticals Incorporated
Grant date
Tue Jul 04 2006 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 29 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61P, A61P15/00, A61P15/08, A61P15/12, A61P15/18